Overview

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Status:
Recruiting

Trial end date:
2027-05-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Diphosphonates